Aktis Oncology

About:

Aktis Oncology is a biotechnology company that designs and develops novel class radiopharmaceuticals.

Website: https://www.aktisoncology.com

Top Investors: RA Capital Management, Eli Lilly, MRL Ventures Fund, Bristol-Myers Squibb, Novartis

Description:

Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes.